← Back to Search

Protein Kinase Inhibitor

CX-4945 for Basal Cell Carcinoma

Phase 1
Waitlist Available
Research Sponsored by Senhwa Biosciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up cycle 1, twenty-eight (28) day continuous dosing schedule
Awards & highlights
No Placebo-Only Group

Summary

This trial tests CX-4945, an oral drug, in patients with advanced or spreading basal cell carcinoma. The drug works by blocking a key pathway that cancer cells need to grow, even if other treatments fail due to mutations.

Eligible Conditions
  • Basal Cell Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~cycle 1, twenty-eight (28) day continuous dosing schedule
This trial's timeline: 3 weeks for screening, Varies for treatment, and cycle 1, twenty-eight (28) day continuous dosing schedule for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Determination of RP2D
Secondary study objectives
Absence of residual BCC in laBCC patients
Adverse Event
Objective response
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Expansion CX-4945 Metastatic BCCExperimental Treatment1 Intervention
CX-4945 capsules at 1000mg BID, on the dosing schedule identified during the Phase I treatment duration increment part of the study
Group II: Expansion CX-4945 Locally Advanced BCCExperimental Treatment1 Intervention
CX-4945 capsules at 1000mg BID, on the dosing schedule identified during the Phase I treatment duration increment part of the study
Group III: CX-4945 28 Day Dose DurationExperimental Treatment1 Intervention
CX-4945 capsules at 1000mg BID, on Days 1 through 28 of each treatment cycle
Group IV: CX-4945 21 Day Dose DurationExperimental Treatment1 Intervention
CX-4945 capsules at 1000mg BID, on Days 1 through 21 of each treatment cycle
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CX-4945
2022
Completed Phase 2
~160

Find a Location

Who is running the clinical trial?

Senhwa Biosciences, Inc.Lead Sponsor
6 Previous Clinical Trials
417 Total Patients Enrolled
John Soong, MD, FCAPStudy DirectorSenhwa Biosciences
1 Previous Clinical Trials
52 Total Patients Enrolled
Jin-Ding Huang, PhDStudy DirectorSenhwa Biosciences
2 Previous Clinical Trials
188 Total Patients Enrolled

Media Library

CX-4945 (Protein Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03897036 — Phase 1
Basal Cell Carcinoma Research Study Groups: CX-4945 28 Day Dose Duration, CX-4945 21 Day Dose Duration, Expansion CX-4945 Locally Advanced BCC, Expansion CX-4945 Metastatic BCC
Basal Cell Carcinoma Clinical Trial 2023: CX-4945 Highlights & Side Effects. Trial Name: NCT03897036 — Phase 1
CX-4945 (Protein Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03897036 — Phase 1
~4 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top